Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Acomplia, Zimulti
Rimonabant is a selective cannabinoid receptor type 1 (CB1) inverse agonist/antagonist that was initially developed and marketed for the treatment of obesity and related metabolic disorders. It acts by blocking the CB1 receptors, which are involved in appetite regulation, lipid metabolism, and glucose homeostasis. While initially showing promise, rimonabant was later withdrawn from the market due to significant psychiatric side effects, including depression, anxiety, and suicidal ideation.
Rimonabant was intended for the treatment of obesity and related metabolic disorders but was withdrawn due to psychiatric side effects.
Outcome:
Increased risk of CNS depression
Mechanism:
Additive CNS depressant effects
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Pharmacodynamic interaction
Outcome:
Potential for decreased rimonabant absorption
Mechanism:
Chelation or altered gastric pH
It is unlikely that further development of rimonabant or similar CB1 antagonists for obesity will occur due to the unfavorable safety profile (Confidence > 95%).
Due to the high rate of psychiatric adverse events observed in clinical trials and post-marketing surveillance, the likelihood of rimonabant being re-approved by regulatory agencies is extremely low (<1%).
Antiobesity Agent, Cannabinoid Receptor Antagonist
2,5-diaryloxazole